Affordability
One batch — many patients
Allogeneic donor-derived therapies reduce manufacturing cost by enabling multi-patient batches.
TiCoBi
One donor.
Up to ten doses.
Thrafford is developing India’s first scalable, off-the-shelf γδ T-cell therapy manufacturing platform, designed to eliminate measurable residual disease (MRD) before it causes AML relapse.
The platform
TiCoBi: Proprietary Time-Controlled Bioprocess
A proprietary, patent-filed, time-controlled bioprocess that expands a single healthy donor’s blood into up to 10 ready-to-use, off-the-shelf γδ T-cell doses — with no viral vectors, no gene editing and no patient-specific manufacturing.
- No gene editing
- No viral vectors
- MHC-independent
- Non-exhausted memory phenotype
- Antigen-agnostic
- Minimal GvHD risk
Healthy donor
Blood from a single healthy donor — not the patient.
γδ T-cell isolation
Gamma-delta T cells are isolated and purified ex vivo.
Time-controlled expansion
Temporally and volumetrically controlled expansion yields a non-exhausted memory phenotype.
Up to 10 doses
Off-the-shelf doses, ready when the clinician needs them.
Immune cells that find leukaemia without a map
Why γδ T cells
Immune-mediated elimination of leukaemia is most likely to work when disease burden is minimal — before overt relapse and an increasingly immunosuppressive microenvironment.
MHC-independent recognition
γδ T cells recognise stress-induced ligands (MICA/B and ULBP family) on residual leukaemic cells, independently of classical HLA presentation.
Graft-versus-leukaemia, minimal GvHD
Potent anti-leukaemic activity with minimal risk of graft-versus-host disease — the basis for allogeneic, off-the-shelf therapy.
Built for repeat dosing
Suited to repeated administration during remission or in the peri-transplant setting, when disease burden is lowest.
Applications
One platform, many cell therapies
Our reagent-agnostic design reaches across oncology and autoimmune disease. Longer term, our AI and quantum computation initiative designs and optimises targets, algorithms and processes.
- CAR-T therapies
- NK & dendritic cell therapies
- Autoimmune & infectious diseases
- Solid tumours & advanced gene editing
Product portfolio
One platform, a growing pipeline
TiCoBi is antigen-agnostic. Beyond AML, the same process extends to glioblastoma, other solid tumours and rheumatoid arthritis — and TiCoBi-generated γδ T cells can also supply partners’ CAR-T programmes.
ProgrammeIndicationModality
TLS-GD-001AM
Acute Myeloid Leukaemia
Lead programmeAllogeneic γδ T cellsTiCoBi
TLS-GD-001GB
Glioblastoma
Allogeneic γδ T cellsTiCoBi
TLS-TRG-001RA
Rheumatoid Arthritis
Allogeneic TRG cellsTiCoBi
TLS-GDC-001LL
Lymphoma & Leukaemia
γδ CD19 CAR-THealthy donor · one batch for 10 patients
Our product vs standard of care
TiCoBi vs today’s AML care
Today’s treatments can bring remission, but leukaemia cells that survive them often bring the disease back. TiCoBi is designed to close that gap.
TopicStandard of care including CAR-TTiCoBi allogeneic γδ T cells
Leftover disease
Standard of care
Treatment can bring remission, but leukaemia cells that survive it drive relapse. No dedicated, scalable treatment exists for them.
TiCoBi
Designed to go after those surviving cells and prevent relapse.
Finding cancer cells
Standard of care
CAR-T looks for one target. In AML that target varies between cancer cells and is often shared with healthy blood cells, and toxicity is a concern.
TiCoBi
γδ T cells recognise several tumour-stress signals with no single target to depend on, so cancer cells may find it harder to escape.
Who it’s made for
Standard of care
CAR-T is manufactured separately for each patient.
TiCoBi
One healthy-donor batch gives multiple doses, with no HLA matching needed.
Cell engineering
Standard of care
CAR-T cells are engineered, using viral vectors or gene editing.
TiCoBi
No viral vectors, no gene editing, and cells that aren’t exhausted.
Time to treatment
Standard of care
Weeks of manufacturing before a patient can be treated.
TiCoBi
Frozen and ready to use, so doses are available quickly.
Role and cost
Standard of care
Cell therapy today is a costly rescue, used after relapse.
TiCoBi
Designed to be affordable at scale, and given to prevent relapse rather than treat it.
Standard of care for AML means 7+3 chemotherapy, azacitidine with venetoclax, targeted therapies and donor stem-cell transplant. These modalities are given mainly for disease management and after relapse. Thrafford’s approach is designed to eliminate measurable residual disease during remission, shifting care from rescue to prevention.
In low- and middle-income countries, including India, accessibility remains a major challenge, which is why adopting PoCMAP can be a revolutionary intervention.
Point-of-care with PoCMAP
Shorter journeys from cell to patient
In conventional manufacturing, a patient’s cells are collected at the hospital, frozen and shipped to a distant facility, then frozen again and shipped back for infusion. Decentralising manufacturing to the hospital removes both journeys, reducing logistics and freeze–thaw cycles.
Hospital 1
Cells collectedOn site, from the patient or donor
Manufactured on-site with PoCMAP 2
- CAR-T
- NK
- Dendritic
In-line QC 4Real-time sterility & quality checks
TreatedIn the same hospital
5Cell to patient without leaving the building: no inter-site shipping and fewer freeze–thaw cycles.
A modular platform built for hospitals
- 1
Decentralised manufacturing
Therapies are produced at the hospital, where the patient is treated.
- 2
Parallel multi-batch processing
Multiple batches run side by side to increase output.
- 3
Platform-compatible
Works with CAR-T, NK and dendritic cell systems.
- 4
Built-in quality control
Real-time sterility and quality control integration.
- 5
Simpler logistics
Reduced logistics and fewer freeze–thaw cycles.
Platform principles
Our three-pillar approach
Affordable. Scalable. Accessible.
Scalability
40× production capacity
Our modular platform delivers up to 40× capacity using parallel multi-batch processing systems.
Accessibility
Therapies closer to home
India’s first point-of-care CAR-T manufacturing system — enabling hospital-based therapy production.
Intellectual property
Protected by design
Our moat combines patent-filed manufacturing with trade-secret process logic — an integrated value chain that takes years of validation to rebuild.
- Patent filed
Application no.
2026••••2935
Temporally and Volumetrically Controlled Process for Ex-vivo Expansion of V-Gamma-9V-Delta-2 T Cells
- Patent filed
Application no.
2025••••8309
Point of Care Manufacturing Platform for Engineered Gamma Delta T cells
- Patent filed
Application no.
2025••••2865
Point of Care Manufacturing and Processing Platform for Cell Therapy
Ongoing project
Conventional vs Quantum AI
We are mapping how human genes, proteins, metabolites, drugs and cells interact, drawing on the largest possible census of biomedical data resources and structuring it for quantum AI. The first goal is a working simulation of the immune system; every layer we add opens new questions, from cancer to autoimmunity and ageing.
Conventional AI
- Scope
- Models one layer of biology at a time, such as gene expression or protein binding, and joins the results afterwards.
- Interactions
- Trims the interactions it considers down to what classical hardware can compute.
- Readiness
- Mature, and in routine use across drug discovery today.
Quantum AI
- Scope
- Aims to hold several layers of human biology inside a single model.
- Interactions
- Explores interaction spaces that grow too quickly for exhaustive classical search.
- Readiness
- Still emerging. We are preparing the data now so it is ready when the hardware is.
Where the map will be used
Predicting adverse reactions
Simulating how a patient’s immune system may respond to a cell therapy, including cytokine release syndrome and neurotoxicity, before the first dose.
Choosing targets
Ranking the stress ligands, receptors and pathways worth pursuing in future γδ T-cell and CAR-T programmes.
Matching patients
Identifying the patients most likely to respond, from the molecular profile of their disease.
Repurposing drugs
Finding approved drugs that act on the same interaction networks as a disease, as candidates for new uses.
Partner with us on TiCoBi
Talk to us about clinical partnerships, our γδ T-cell programmes, or supplying γδ T cells for your CAR-T pipeline.